Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL95723 | 0.75 | ERN1 (0.50) | ERN1 | |
| SCHEMBL13179007 | 0.75 | ERN1 (0.30) | ERN1 | |
| SCHEMBL4720705 | 0.74 | ERN1 (0.36) | ERN1 | |
| SCHEMBL25819841 | 0.74 | CYP3A4 (0.31) | — | |
| SCHEMBL25819840 | 0.71 | ESR1 (0.30) | — | |
| SCHEMBL29956613 | 0.70 | ERN1 (0.42) | ERN1 | |
| SCHEMBL10224884 | 0.67 | ERN1 (0.39) | ERN1 | |
| SCHEMBL29921076 | 0.66 | ERN1 (0.42) | ERN1 | |
| SCHEMBL19126505 | 0.66 | ERN1 (0.42) | ERN1 | |
| SCHEMBL29824002 | 0.66 | ERN1 (0.42) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442701-B2 | Amino-heterocycles as VR-1 antagonists for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2008-10-28 | — | — | US | disclosed |
| EP-1562934-B1 | AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME (GB) | 2008-03-26 | — | — | EP | disclosed |
| US-7285563-B2 | Heteroaromatic urea derivatives as VR-1 receptor modulators for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2007-10-23 | — | — | US | disclosed |
| US-20060040947-A1 | Amino-heterocycles as vr-1 antagonists for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2006-02-23 | — | — | US | disclosed |
| EP-1562934-A1 | AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME LTD. (GB) | 2005-08-17 | — | — | EP | disclosed |
| US-20050107388-A1 | Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2005-05-19 | — | — | US | disclosed |
| EP-1490340-A1 | HETEROAROMATIC UREA DERIVATIVES AS VR-1 RECEPTOR MODULATORS FOR TREATING PAIN | MERCK SHARP & DOHME LTD. (GB) | 2004-12-29 | — | — | EP | disclosed |
| WO-2004046133-A1 | AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2004-06-03 | — | — | WO | disclosed |
| WO-2003080578-A1 | HETEROAROMATIC UREA DERIVATIVES AS VR-1 RECEPTOR MODULATORS FOR TREATING PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107388-A1 | Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain | ARRB1, OPRL1, CNR1 | ERN1 787/4885 |
| US-20060040947-A1 | Amino-heterocycles as vr-1 antagonists for treating pain | OPRL1, CNR1, GPR6 | ERN1 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.